Anti-TNF therapy efficacious for preventing endoscopic recurrence in Crohn’s
Click Here to Manage Email Alerts
After surgery for Crohn’s disease, anti-tumor necrosis factor therapy was efficacious for preventing endoscopic recurrence without an increase in the incidence of adverse events, according to study results.
“However, clinical recurrence was not significantly reduced,” Motoi Uchino, MD, PhD, from the department of inflammatory bowel disease at Hyogo College of Medicine, and colleagues wrote. “The efficacy of postoperative antiTNF therapy may differ in terms of the outcomes, which include longterm prevention, the avoidance of further surgery and costeffectiveness.”
Uchino and colleagues conducted a systematic literature review of studies that investigated anti-TNF therapy, CD and postoperative recurrence. Investigators identified eight studies comprising a total of 570 patients; 254 patients in the intervention group receiving anti-TNF therapy and 316 patients in the control group. They performed meta-analyses to assess endoscopic and clinical recurrence and adverse events in all patients .
Results showed a relative risk of 0.34 for the efficacy of anti-TNF therapy for the prevention of endoscopic recurrence (95% CI, 0.220.53) and a RR of 0.6 for clinical recurrence (95% CI, 0.361.02). Investigators reported the adverse event anti-TNF therapy RR was 1.75 (95% CI, 0.813.79).
Collapse
Read more about
Click Here to Manage Email Alerts